Safety, pharmacokinetics and efficacy of selumetinib in Chinese adult and paediatric patients with neurofibromatosis type 1 and inoperable plexiform neurofibromas: The primary analysis of a phase 1 open‐label study

Documenti analoghi

• A phase I, randomized, placebo‐controlled trial to evaluate the pharmacokinetics, safety, and tolerability of nirsevimab in healthy Chinese adults
  di: Xiaomeng Mao, et al.
  Pubblicazione: (2024)
• Safety, pharmacokinetics, and food effect of sudapyridine (WX‐081), a novel anti‐tuberculosis candidate in healthy Chinese subjects
  di: Chengyin Yu, et al.
  Pubblicazione: (2024)
• Safety and efficacy of isocitrate dehydrogenase‐1 inhibitor ivosidenib in patients with cholangiocarcinoma
  di: Lindsay Wong, et al.
  Pubblicazione: (2026)
• A pharmacokinetic study comparing the biosimilar HEC14028 and Dulaglutide (Trulicity®) in healthy Chinese subjects
  di: Xianglei Gao, et al.
  Pubblicazione: (2024)
• Safety, pharmacokinetics, and pharmacodynamics in healthy Chinese volunteers treated with SC0062, a highly selective endothelin‐A receptor antagonist
  di: Yun Liu, et al.
  Pubblicazione: (2024)